Robert Paul Hasserjian, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myelodysplastic Syndromes | 70 | 2024 | 1376 | 11.540 |
Why?
|
| Leukemia, Myeloid, Acute | 65 | 2024 | 3589 | 7.800 |
Why?
|
| Myeloproliferative Disorders | 41 | 2024 | 618 | 7.590 |
Why?
|
| Bone Marrow | 62 | 2024 | 2902 | 6.040 |
Why?
|
| Leukemia, Erythroblastic, Acute | 10 | 2018 | 176 | 2.520 |
Why?
|
| Chromosome Aberrations | 24 | 2023 | 1767 | 2.320 |
Why?
|
| World Health Organization | 17 | 2024 | 1294 | 2.030 |
Why?
|
| Hodgkin Disease | 12 | 2022 | 1377 | 1.820 |
Why?
|
| Leukemia, Myeloid | 7 | 2019 | 695 | 1.780 |
Why?
|
| Mutation | 68 | 2024 | 29706 | 1.740 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 5 | 2022 | 15 | 1.490 |
Why?
|
| Hematologic Neoplasms | 16 | 2023 | 1864 | 1.460 |
Why?
|
| Lymphoma, Follicular | 11 | 2024 | 450 | 1.380 |
Why?
|
| Leukemia, Neutrophilic, Chronic | 2 | 2019 | 12 | 1.260 |
Why?
|
| Janus Kinase 2 | 14 | 2024 | 536 | 1.240 |
Why?
|
| Leukocytosis | 4 | 2016 | 251 | 1.220 |
Why?
|
| Neoplasms, Second Primary | 5 | 2023 | 1051 | 1.180 |
Why?
|
| Reticulin | 4 | 2014 | 19 | 1.130 |
Why?
|
| Hypereosinophilic Syndrome | 5 | 2023 | 96 | 1.100 |
Why?
|
| Immunophenotyping | 25 | 2022 | 1861 | 1.100 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 7 | 2020 | 679 | 1.100 |
Why?
|
| Primary Myelofibrosis | 7 | 2023 | 215 | 1.080 |
Why?
|
| Chromosome Deletion | 4 | 2017 | 1387 | 1.000 |
Why?
|
| Diagnosis, Differential | 48 | 2022 | 12901 | 0.990 |
Why?
|
| Prognosis | 50 | 2024 | 29337 | 0.970 |
Why?
|
| Calreticulin | 4 | 2020 | 114 | 0.920 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 10 | 2022 | 495 | 0.910 |
Why?
|
| Leukemia | 11 | 2023 | 1500 | 0.910 |
Why?
|
| Lymph Nodes | 13 | 2021 | 3474 | 0.910 |
Why?
|
| Hematologic Diseases | 4 | 2023 | 494 | 0.900 |
Why?
|
| Bone Marrow Examination | 10 | 2017 | 156 | 0.870 |
Why?
|
| Tandem Repeat Sequences | 2 | 2022 | 181 | 0.860 |
Why?
|
| Bone Marrow Cells | 10 | 2021 | 2416 | 0.860 |
Why?
|
| Humans | 272 | 2024 | 752411 | 0.840 |
Why?
|
| Thrombocythemia, Essential | 3 | 2018 | 107 | 0.820 |
Why?
|
| Karyotyping | 9 | 2017 | 1182 | 0.820 |
Why?
|
| Leukemia, Eosinophilic, Acute | 1 | 2021 | 5 | 0.810 |
Why?
|
| Nuclear Proteins | 19 | 2023 | 5785 | 0.790 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 4 | 2020 | 93 | 0.760 |
Why?
|
| Aged, 80 and over | 68 | 2024 | 58299 | 0.750 |
Why?
|
| Biopsy | 29 | 2023 | 6743 | 0.740 |
Why?
|
| Oral Ulcer | 1 | 2021 | 95 | 0.740 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2022 | 2896 | 0.730 |
Why?
|
| Core Binding Factors | 1 | 2020 | 29 | 0.720 |
Why?
|
| Lymphoma, B-Cell | 7 | 2015 | 929 | 0.720 |
Why?
|
| Flow Cytometry | 15 | 2022 | 5838 | 0.710 |
Why?
|
| Chromosomes, Human, Pair 20 | 2 | 2011 | 127 | 0.690 |
Why?
|
| Neoplasm Proteins | 6 | 2022 | 3599 | 0.690 |
Why?
|
| Aged | 104 | 2024 | 166585 | 0.660 |
Why?
|
| Herpesvirus 4, Human | 9 | 2022 | 1063 | 0.660 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2011 | 102 | 0.660 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2024 | 430 | 0.660 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 9 | 2024 | 1395 | 0.660 |
Why?
|
| Thymus Neoplasms | 4 | 2015 | 273 | 0.650 |
Why?
|
| Pancytopenia | 4 | 2016 | 101 | 0.640 |
Why?
|
| Gene Rearrangement | 9 | 2022 | 1112 | 0.630 |
Why?
|
| Pathology, Clinical | 2 | 2019 | 367 | 0.620 |
Why?
|
| Diagnostic Techniques and Procedures | 1 | 2020 | 217 | 0.610 |
Why?
|
| Ring Chromosomes | 1 | 2017 | 19 | 0.600 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 2 | 2019 | 179 | 0.600 |
Why?
|
| Male | 146 | 2024 | 354908 | 0.600 |
Why?
|
| Polycythemia Vera | 3 | 2017 | 158 | 0.590 |
Why?
|
| Adult | 111 | 2024 | 216927 | 0.580 |
Why?
|
| Eosinophilia | 5 | 2024 | 556 | 0.580 |
Why?
|
| Abdomen | 1 | 2023 | 1112 | 0.580 |
Why?
|
| Phosphoproteins | 4 | 2020 | 2424 | 0.580 |
Why?
|
| Chromosome Inversion | 2 | 2017 | 118 | 0.580 |
Why?
|
| Middle Aged | 116 | 2024 | 217039 | 0.580 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2016 | 49 | 0.570 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 3 | 2021 | 124 | 0.560 |
Why?
|
| Burkitt Lymphoma | 3 | 2010 | 330 | 0.560 |
Why?
|
| Dendritic Cell Sarcoma, Follicular | 3 | 2022 | 30 | 0.560 |
Why?
|
| Hematology | 2 | 2023 | 235 | 0.550 |
Why?
|
| Biological Products | 2 | 2023 | 903 | 0.550 |
Why?
|
| Megakaryocytes | 4 | 2018 | 560 | 0.550 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 2174 | 0.540 |
Why?
|
| Mastocytosis, Systemic | 2 | 2023 | 102 | 0.530 |
Why?
|
| Epstein-Barr Virus Infections | 5 | 2022 | 596 | 0.530 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2015 | 1373 | 0.530 |
Why?
|
| Fatal Outcome | 12 | 2012 | 1828 | 0.520 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2021 | 1517 | 0.520 |
Why?
|
| Female | 132 | 2024 | 386085 | 0.520 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 2015 | 48 | 0.510 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2017 | 343 | 0.510 |
Why?
|
| Anemia, Macrocytic | 1 | 2015 | 54 | 0.510 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 994 | 0.510 |
Why?
|
| Chromosomes, Human | 1 | 2017 | 445 | 0.510 |
Why?
|
| Genetic Testing | 3 | 2019 | 3506 | 0.500 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 355 | 0.490 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2014 | 16 | 0.490 |
Why?
|
| Myeloid Cells | 3 | 2018 | 815 | 0.490 |
Why?
|
| DNA Copy Number Variations | 3 | 2022 | 2007 | 0.480 |
Why?
|
| Immunohistochemistry | 27 | 2022 | 11008 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 14 | 2019 | 11587 | 0.480 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 11 | 2021 | 5551 | 0.470 |
Why?
|
| Thymoma | 2 | 2007 | 186 | 0.470 |
Why?
|
| Mediastinal Neoplasms | 3 | 2016 | 401 | 0.470 |
Why?
|
| DNA Mutational Analysis | 11 | 2022 | 4110 | 0.470 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2019 | 6501 | 0.460 |
Why?
|
| Neoplasms | 15 | 2023 | 21806 | 0.450 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 3 | 2022 | 265 | 0.440 |
Why?
|
| Sarcoma, Myeloid | 4 | 2023 | 52 | 0.430 |
Why?
|
| Precancerous Conditions | 2 | 2019 | 969 | 0.430 |
Why?
|
| T-Lymphocytes | 7 | 2018 | 10035 | 0.420 |
Why?
|
| Blast Crisis | 3 | 2024 | 101 | 0.410 |
Why?
|
| Cytogenetic Analysis | 7 | 2022 | 272 | 0.410 |
Why?
|
| Young Adult | 39 | 2024 | 57632 | 0.400 |
Why?
|
| Stem Cell Transplantation | 4 | 2018 | 1600 | 0.400 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 3 | 2023 | 302 | 0.400 |
Why?
|
| Thrombocytopenia | 4 | 2015 | 1170 | 0.390 |
Why?
|
| Genomics | 7 | 2022 | 5728 | 0.390 |
Why?
|
| Erythroid Cells | 3 | 2021 | 235 | 0.390 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 606 | 0.390 |
Why?
|
| Antigens, CD20 | 3 | 2009 | 202 | 0.390 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 5 | 2015 | 1626 | 0.390 |
Why?
|
| Cytogenetics | 4 | 2022 | 197 | 0.390 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 5 | 2024 | 1391 | 0.390 |
Why?
|
| Lymphoproliferative Disorders | 2 | 2018 | 531 | 0.380 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 3 | 2022 | 167 | 0.380 |
Why?
|
| Acute Kidney Injury | 1 | 2023 | 1882 | 0.380 |
Why?
|
|